capsid assembly inhibitors (Arbutus Biopharma/Roivant)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Namecapsid assembly inhibitors (Arbutus Biopharma/Roivant)
Drug Alias NameFSBA derivatives (Enantigen)capsid assembly inhibitors (Arbutus Biopharma)pregenomic RNA encapsidation inhibitors (Enantigen)sulfamoylbenzamide derivatives (Enantigen)viral capsid assembly inhibitors (OnCore Biopharma) +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis B virus replication inhibitors
TargetsUpdating
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEnantigen Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEnantigen Therapeutics IncOnCore Biopharma IncRoivant Sciences Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsHepatitis B

Other Information

ATC CodeN/A
Related LinksN/A